#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
CG Oncology attracted some attention last month at #AACR22 for its early data on its oncolytic virus paired with Merck’s Keytruda for bladder cancer, and updated numbers from ASCO don’t disappoint.
In a Phase II study, 22 out of 24 patients have had a complete response to the combo treatment at an early 3-month check-in, good for a 92% initial response rate. At 6 months, that drops to 14 of 16, and at one year — the primary endpoint of the study — 6 of 8 patients maintained a complete response.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.